MCID: SKN019
MIFTS: 67

Skin Melanoma

Categories: Cancer diseases, Ear diseases, Skin diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 56 15
Cutaneous Melanoma 12 30 6 15 17 74
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 45
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8923
ICD9CM 36 172 172.9
MeSH 45 C562393
NCIt 51 C3510
SNOMED-CT 69 93655004
ICD10 34 C43 C43.9

Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and acral lentiginous melanoma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is LINC00937 (Long Intergenic Non-Protein Coding RNA 937), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Intron A and Keytruda have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and brain, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 33.6 BRAF CDKN2A CDKN2B MITF NRAS TP53
2 acral lentiginous melanoma 32.2 BRAF CDKN2A NRAS
3 melanoma 30.6 BRAF CDKN2A MCAM MIA MITF NRAS
4 mucosal melanoma 30.3 BRAF MITF NRAS
5 vitiligo-associated multiple autoimmune disease susceptibility 1 30.2 MITF PMEL TYR
6 spitz nevus 30.0 BRAF CDKN2A TP53
7 li-fraumeni syndrome 30.0 CDKN1A CDKN2A MDM2 TP53
8 melanoma, uveal 29.9 BRAF CDKN2A MITF MMP2 NRAS PMEL
9 retinoblastoma 29.7 CDKN1A CDKN2A MDM2 TP53
10 thyroid cancer 29.6 BRAF CASP3 CDKN1A NRAS TP53
11 lymphoma, non-hodgkin, familial 29.5 BRAF CASP3 CDKN2B MDM2 NRAS TP53
12 squamous cell carcinoma 29.4 BRAF CDKN2A MMP2 NME1 PTGS2 TP53
13 hepatocellular carcinoma 27.2 CASP3 CDKN1A CDKN2A DRAIC FGF2 MMP2
14 breast cancer 27.1 BRAF CASP3 CDKN1A DRAIC FGF2 MDM2
15 melanoma, cutaneous malignant 2 12.6
16 melanoma, cutaneous malignant 3 12.6
17 melanoma, cutaneous malignant 5 12.6
18 melanoma, cutaneous malignant 6 12.6
19 melanoma, cutaneous malignant 9 12.6
20 melanoma, cutaneous malignant 10 12.6
21 melanoma, cutaneous malignant 8 12.6
22 melanoma, cutaneous malignant 4 12.4
23 melanoma, cutaneous malignant 7 12.4
24 superficial spreading melanoma 11.4
25 skin carcinoma 11.4
26 skin/hair/eye pigmentation, variation in, 3 11.4
27 tumor predisposition syndrome 11.3
28 skin amelanotic melanoma 11.1
29 amelanotic melanoma 11.1
30 meningeal melanoma 10.5 CDKN2A MITF
31 malignant leptomeningeal tumor 10.5 CDKN2A MITF
32 albinism, ocular, with late-onset sensorineural deafness 10.5 MITF TYR
33 gallbladder melanoma 10.4 MITF PMEL
34 nevus of ota 10.4 BRAF TP53
35 albinism, ocular, with sensorineural deafness 10.4 MITF TYR
36 halo nevi 10.4 PMEL TYR
37 ring chromosome 7 10.4 MDM2 TP53
38 zika virus infection 10.4 MDM2 TP53
39 scrotal carcinoma 10.4 CDKN2A CDKN2B TP53
40 meningeal melanomatosis 10.4 CDKN2A NRAS TP53
41 histiocytic sarcoma 10.4 BRAF CDKN2A
42 vitiligo-associated multiple autoimmune disease susceptibility 6 10.4 MITF PMEL TYR
43 bladder squamous cell carcinoma 10.4 BRAF CDKN2A TP53
44 pigmented basal cell carcinoma 10.3 MITF TYR
45 hermansky-pudlak syndrome 3 10.3 MITF PMEL TYR
46 epithelioid cell melanoma 10.3 MCAM MITF TYR
47 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
48 lentigo maligna melanoma 10.3 MITF MMP2
49 vulvar intraepithelial neoplasia 10.3 MMP2 TP53
50 leukemia, acute lymphoblastic 3 10.3 CDKN2A CDKN2B TP53

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


pruritus, exanthema

MGI Mouse Phenotypes related to Skin Melanoma:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
2 behavior/neurological MP:0005386 10.41 BRAF CASP3 CDKN1A CDKN2A FGF2 MCAM
3 hematopoietic system MP:0005397 10.41 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
4 cardiovascular system MP:0005385 10.4 BRAF CASP3 CDKN1A CDKN2A FGF2 MCAM
5 cellular MP:0005384 10.4 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
6 endocrine/exocrine gland MP:0005379 10.4 BRAF CASP3 CDKN1A CDKN2A CDKN2B MDM2
7 integument MP:0010771 10.38 BRAF CASP3 CDKN1A CDKN2A CDKN2B MDM2
8 growth/size/body region MP:0005378 10.36 BRAF CASP3 CDKN1A CDKN2A MDM2 MITF
9 immune system MP:0005387 10.36 BRAF CASP3 CDKN1A CDKN2A CDKN2B MCAM
10 mortality/aging MP:0010768 10.34 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
11 craniofacial MP:0005382 10.26 BRAF CASP3 CDKN1A MDM2 MITF MMP2
12 embryo MP:0005380 10.25 BRAF CDKN1A CDKN2A MDM2 MITF NRAS
13 neoplasm MP:0002006 10.23 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
14 digestive/alimentary MP:0005381 10.21 BRAF CASP3 CDKN1A CDKN2A MDM2 NRAS
15 nervous system MP:0003631 10.21 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
16 no phenotypic analysis MP:0003012 10.18 CASP3 CDKN1A CDKN2A CDKN2B MCAM MDM2
17 muscle MP:0005369 10.13 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
18 hearing/vestibular/ear MP:0005377 10.12 BRAF CASP3 CDKN1A FGF2 MITF TP53
19 liver/biliary system MP:0005370 10.11 BRAF CDKN1A CDKN2A MDM2 NME1 NRAS
20 limbs/digits/tail MP:0005371 10.07 BRAF CDKN1A MDM2 MITF NRAS TP53
21 pigmentation MP:0001186 10.02 BRAF CASP3 CDKN2A MDM2 MITF NRAS
22 reproductive system MP:0005389 10 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
23 renal/urinary system MP:0005367 9.92 BRAF CASP3 CDKN1A CDKN2B MDM2 PTGS2
24 skeleton MP:0005390 9.77 BRAF CASP3 CDKN1A CDKN2A FGF2 MDM2
25 respiratory system MP:0005388 9.7 BRAF CASP3 CDKN1A CDKN2A MMP2 PTGS2
26 vision/eye MP:0005391 9.4 BRAF CASP3 CDKN1A CDKN2A FGF2 MITF

Drugs & Therapeutics for Skin Melanoma

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Intron A 19 50 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
2
Keytruda 19 50 PEMBROLIZUMAB Merck September 2014
3
Mekinist 19 50 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
4
Opdivo 19 50 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
5
Proleukin 19 50 ALDESLEUKIN Chiron January 1998
6
Sylatron 19 50 PEGINTERFERON ALFA-2B Merck April 2011
7
Tafinlar 19 50 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
8
Yervoy 19 50 IPILIMUMAB Bristol-Myers Squibb March 2011
9
Zelboraf 19 50 VEMURAFENIB Roche August of 2011

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 728)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
4
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
5
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
6
Pembrolizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 1374853-91-4
7
Sargramostim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 123774-72-1, 83869-56-1
8
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
9
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
10
Everolimus Approved Phase 4,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177 70789204
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
13
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
14
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
15
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 477202-00-9
16
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
17
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 571190-30-2 11431660 5005498 5330286
18
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
19
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
20
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
21
Etanercept Approved, Investigational Phase 4 185243-69-0
22
Aminolevulinic acid Approved Phase 4,Phase 2,Not Applicable 106-60-5 137
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 62-33-9, 60-00-4 6049
25
Pentetic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 67-43-6
26
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
27
Simvastatin Approved Phase 4 79902-63-9 54454
28
Adalimumab Approved Phase 4 331731-18-1 16219006
29
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
30
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
31
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
32
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
33
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
34
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
35
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
36
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
37
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
38
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
39
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4, 585-88-6 493591
40
Lapatinib Approved March 2007, Investigational Phase 4,Phase 3,Phase 2 388082-78-8, 231277-92-2 208908 9941095
41 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
46 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
48 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
49 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2614)
# Name Status NCT ID Phase Drugs
1 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
2 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
3 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
6 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
7 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
8 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
9 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
10 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
11 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
12 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
13 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
14 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
15 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
16 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
17 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
18 Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
19 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
20 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
21 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
22 Flu Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
23 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
24 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
25 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
26 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
27 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
28 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
29 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
30 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
31 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
32 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
33 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
34 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
35 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
36 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
37 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
38 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
39 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
40 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
41 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
42 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
43 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
44 Thymosin-α1 in Cancer-Related Fatigue Unknown status NCT02127268 Phase 3 Thymosin-α1
45 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
46 PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Completed NCT00221702 Phase 3 PegIntron;intron A
47 Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Completed NCT00003444 Phase 3
48 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
49 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
50 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Genetic tests related to Skin Melanoma:

# Genetic test Affiliating Genes
1 Cutaneous Melanoma 30

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

42
Skin, Lymph Node, Brain, T Cells, Testes, Kidney, Eye

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 2738)
# Title Authors Year
1
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma. ( 30769330 )
2019
2
Li-Fraumeni syndrome presenting as cutaneous melanoma in a child: case report and review of literature. ( 30653764 )
2019
3
Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential Mechanisms of Early- and Late-Onset Melanoma. ( 30871230 )
2019
4
LAG-3 and TIGIT protein expressions in cutaneous melanoma and their relationship with PD-1 tumor-infiltrating lymphocytes. ( 30880064 )
2019
5
Influence of functional variants Asp312Asn and Lys751Gln of Xeroderma Pigmentosum Group D (XPD) and Glutathione S-transferase Mu 1 (GSTM1) and Theta 1 (GSTT1) genes on cutaneous melanoma susceptibility and prognosis. ( 30883948 )
2019
6
Differences in cutaneous melanoma outcomes with changes in lymphoscintigraphy timings? ( 30890284 )
2019
7
Metastatic Cutaneous Melanoma Presenting With Melanoma-Associated Retinopathy. ( 30893173 )
2019
8
Comment on "Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy". ( 30899087 )
2019
9
Reply to Comment on "Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy". ( 30899089 )
2019
10
Angiotropism in primary cutaneous melanoma is associated with disease progression and distant metastases: a retrospective study of 179 cases. ( 30903664 )
2019
11
Novel lymph node segmentation and proliferation index measurement for skin melanoma biopsy images. ( 30822606 )
2019
12
Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. ( 30833299 )
2019
13
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. ( 30835257 )
2019
14
Utility of Multistep Protocols in the Analysis of Sentinel Lymph Nodes in Cutaneous Melanoma: An Assessment of 194 Cases. ( 30855172 )
2019
15
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. ( 30860590 )
2019
16
Erratum: Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. ( 30863311 )
2019
17
Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case-control study. ( 30787091 )
2019
18
Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. ( 30800067 )
2019
19
Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma. ( 30816996 )
2019
20
Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature! ( 30740172 )
2019
21
Irbesartan Induced Cutaneous Melanoma! Second Case in the Medical Literature! ( 30740174 )
2019
22
Parotidectomy in patients with head and neck cutaneous melanoma with cervical lymph node involvement. ( 30762921 )
2019
23
Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. ( 30765270 )
2019
24
Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. ( 30773503 )
2019
25
Accuracy of partial biopsies in the management of cutaneous melanoma. ( 30773625 )
2019
26
Radiosensitizing properties of magnetic hyperthermia mediated by superparamagnetic iron oxide nanoparticles (SPIONs) on human cutaneous melanoma cell lines. ( 30774558 )
2019
27
Age as key factor for pattern, timing and extent of distant metastasis in patients with cutaneous melanoma. A study of the German Central Malignant Melanoma Registry. ( 30703453 )
2019
28
Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma. ( 30719636 )
2019
29
Declining Recommended Surgery in Primary Cutaneous Melanoma: An Analysis of Risk Factors and Survival. ( 30719760 )
2019
30
Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma. ( 30721246 )
2019
31
A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. ( 30723592 )
2019
32
Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study. ( 30671928 )
2019
33
Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma. ( 30672662 )
2019
34
Expression of cancer/testis antigens in cutaneous melanoma: a systematic review. ( 30615012 )
2019
35
Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases. ( 30624578 )
2019
36
Early and late relapses of cutaneous melanoma patients. ( 30644788 )
2019
37
Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. ( 30548543 )
2019
38
Cutaneous Melanoma-A Review in Detection, Staging, and Management. ( 30497675 )
2019
39
Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. ( 30447951 )
2019
40
Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis. ( 30431060 )
2019
41
Guidelines of care for the management of primary cutaneous melanoma. ( 30392755 )
2019
42
Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. ( 30326165 )
2019
43
Expression of Ki-67 and Estrogen Receptor Beta in Primary Cutaneous Melanoma as a Potential Indicator of Regional Lymph Node Positivity. ( 28549035 )
2019
44
Targeted Photodynamic-Induced Singlet Oxygen Production by Peptide-Conjugated Biodegradable Nanoparticles for Treatment of Skin Melanoma. ( 29885810 )
2018
45
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
46
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. ( 29794562 )
2018
47
Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study. ( 29978471 )
2018
48
Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation. ( 29767233 )
2018
49
Macrophages in skin melanoma-the key element in melanomagenesis. ( 29552183 )
2018
50
Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016. ( 29120964 )
2018

Variations for Skin Melanoma

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 1910)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5611215 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 6:57148199-57148199 0
2 COSM5611210 YAP1 skin,neck,malignant melanoma,NS c.1129C>T p.Q377* 11:102229716-102229716 0
3 COSM5611204 XRCC6 skin,scalp,malignant melanoma,NS c.1054C>T p.P352S 22:41650816-41650816 0
4 COSM5611206 XRCC6 skin,scalp,malignant melanoma,NS c.1422-1G>T p.? 22:41658251-41658251 0
5 COSM5611205 XRCC6 skin,scalp,malignant melanoma,NS c.238C>T p.R80* 22:41636155-41636155 0
6 COSM1703787 WT1 skin,neck,malignant melanoma,NS c.1169G>A p.R390Q 11:32392031-32392031 0
7 COSM5611184 WT1 skin,scalp,malignant melanoma,NS c.837C>T p.P279P 11:32400005-32400005 0
8 COSM5611196 WT1 skin,scalp,malignant melanoma,NS c.651G>A p.L217L 11:32427973-32427973 0
9 COSM5611193 WT1 skin,scalp,malignant melanoma,NS c.538G>A p.D180N 11:32428524-32428524 0
10 COSM3446776 WT1 skin,scalp,malignant melanoma,NS c.820G>A p.D274N 11:32400022-32400022 0
11 COSM5879179 WT1 skin,scalp,malignant melanoma,NS c.1288G>A p.E430K 11:32389120-32389120 0
12 COSM5611190 WT1 skin,scalp,malignant melanoma,NS c.528C>T p.F176F 11:32428534-32428534 0
13 COSM5611187 WT1 skin,scalp,malignant melanoma,NS c.1253G>A p.W418* 11:32389155-32389155 0
14 COSM5611165 WRN skin,neck,malignant melanoma,NS c.1785C>A p.I595I 8:31090898-31090898 0
15 COSM5611174 WRN skin,scalp,malignant melanoma,NS c.3898C>T p.P1300S 8:31157446-31157446 0
16 COSM5611169 WRN skin,scalp,malignant melanoma,NS c.866C>T p.S289L 8:31080893-31080893 0
17 COSM3512552 VAT1L skin,neck,malignant melanoma,NS c.246C>T p.F82F 16:77816933-77816933 0
18 COSM5611155 VAT1L skin,scalp,malignant melanoma,NS c.430G>A p.E144K 16:77825312-77825312 0
19 COSM5611159 VAT1L skin,scalp,malignant melanoma,NS c.985G>A p.G329S 16:77884710-77884710 0
20 COSM5611154 VAT1L skin,scalp,malignant melanoma,NS c.503C>T p.A168V 16:77825385-77825385 0
21 COSM5611151 USP9X skin,scalp,malignant melanoma,NS c.3985T>C p.F1329L 23:41196279-41196279 0
22 COSM5611149 USP9X skin,scalp,malignant melanoma,NS c.5195C>T p.T1732I 23:41214594-41214594 0
23 COSM5611132 UGT1A1 skin,scalp,malignant melanoma,NS c.256G>A p.E86K 2:233760543-233760543 0
24 COSM5611117 TSHR skin,scalp,malignant melanoma,NS c.2043C>T p.F681F 14:81144101-81144101 0
25 COSM4819845 TSHR skin,scalp,malignant melanoma,NS c.291C>T p.F97F 14:81068302-81068302 0
26 COSM5611104 TSC2 skin,neck,malignant melanoma,NS c.626C>T p.T209I 16:2056222-2056222 0
27 COSM5611110 TSC2 skin,scalp,malignant melanoma,NS c.2109G>A p.W703* 16:2072252-2072252 0
28 COSM5611108 TSC2 skin,scalp,malignant melanoma,NS c.2632C>T p.P878S 16:2075885-2075885 0
29 COSM5611106 TSC2 skin,scalp,malignant melanoma,NS c.3347C>T p.A1116V 16:2079619-2079619 0
30 COSM5611095 TSC1 skin,scalp,malignant melanoma,NS c.995C>T p.S332F 9:132911487-132911487 0
31 COSM5611088 TSC1 skin,scalp,malignant melanoma,NS c.248C>T p.A83V 9:132925702-132925702 0
32 COSM5611093 TSC1 skin,scalp,malignant melanoma,NS c.1A>T p.M1L 9:132928872-132928872 0
33 COSM5611072 TRRAP skin,neck,malignant melanoma,NS c.9716C>T p.P3239L 7:98992171-98992171 0
34 COSM5611046 TRRAP skin,scalp,malignant melanoma,NS c.3407C>T p.P1136L 7:98930646-98930646 0
35 COSM5611044 TRRAP skin,scalp,malignant melanoma,NS c.3310G>A p.E1104K 7:98930123-98930123 0
36 COSM5611024 TRRAP skin,scalp,malignant melanoma,NS c.5116C>G p.R1706G 7:98950119-98950119 0
37 COSM5611082 TRRAP skin,trunk,malignant melanoma,NS c.100C>T p.P34S 7:98881250-98881250 0
38 COSM5611050 TRRAP skin,scalp,malignant melanoma,NS c.8151G>A p.E2717E 7:98976749-98976749 0
39 COSM5611070 TRRAP skin,neck,malignant melanoma,NS c.687C>T p.P229P 7:98899475-98899475 0
40 COSM5611064 TRRAP skin,neck,malignant melanoma,NS c.3048G>A p.K1016K 7:98927239-98927239 0
41 COSM1176879 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 0
42 COSM5611048 TRRAP skin,scalp,malignant melanoma,NS c.8119C>T p.P2707S 7:98976717-98976717 0
43 COSM5611066 TRRAP skin,neck,malignant melanoma,NS c.4150G>C p.E1384Q 7:98937194-98937194 0
44 COSM5611080 TRRAP skin,scalp,malignant melanoma,NS c.3597C>T p.S1199S 7:98931410-98931410 0
45 COSM5611062 TRRAP skin,scalp,malignant melanoma,NS c.6763A>G p.M2255V 7:98964637-98964637 0
46 COSM5611056 TRRAP skin,scalp,malignant melanoma,NS c.1568C>T p.P523L 7:98910273-98910273 0
47 COSM5610981 TRPM3 skin,scalp,malignant melanoma,NS c.2357G>A p.G786E 9:70603361-70603361 0
48 COSM2779303 TRPM3 skin,neck,malignant melanoma,NS c.3620G>A p.R1207Q 9:70537073-70537073 0
49 COSM5610949 TRPM3 skin,scalp,malignant melanoma,NS c.4572G>A p.K1524K 9:70536121-70536121 0
50 COSM5610977 TRPM3 skin,neck,malignant melanoma,NS c.2449G>A p.D817N 9:70598598-70598598 0

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
2
Show member pathways
13.75 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
3
Show member pathways
13.38 BRAF CASP3 CDKN1A FGF2 MMP2 NRAS
4
Show member pathways
13.02 CASP3 CDKN1A FGF2 MDM2 NRAS PTGS2
5
Show member pathways
12.99 CASP3 CDKN1A CDKN2A FGF2 MDM2 NRAS
6
Show member pathways
12.91 BRAF CASP3 CDKN1A CDKN2A MDM2 NRAS
7
Show member pathways
12.84 CASP3 CDKN1A CDKN2A MDM2 NRAS TP53
8 12.79 BRAF CASP3 FGF2 NRAS TP53
9
Show member pathways
12.79 BRAF CDKN1A CDKN2A CDKN2B FGF2 NRAS
10
Show member pathways
12.76 CDKN1A FGF2 MDM2 NRAS TP53
11
Show member pathways
12.74 BRAF CASP3 NRAS PTGS2 TP53
12
Show member pathways
12.62 CDKN1A FGF2 MMP2 NRAS TP53
13
Show member pathways
12.62 BRAF CDKN1A MDM2 NRAS TP53
14
Show member pathways
12.6 CDKN1A CDKN2A CDKN2B MDM2 TP53
15
Show member pathways
12.46 CASP3 MDM2 NRAS TP53
16 12.45 CASP3 CDKN1A CDKN2A MDM2 NRAS PTGS2
17
Show member pathways
12.45 BRAF CDKN1A CDKN2A CDKN2B FGF2 MDM2
18
Show member pathways
12.44 BRAF MITF NRAS PTGS2
19
Show member pathways
12.42 CASP3 CDKN1A CDKN2A MDM2 TP53
20 12.41 CDKN1A CDKN2A CDKN2B MDM2 TP53
21 12.4 CDKN1A CDKN2A CDKN2B NRAS TP53
22
Show member pathways
12.38 CDKN1A CDKN2A CDKN2B TP53
23
Show member pathways
12.3 BRAF CASP3 MITF NRAS TP53
24 12.28 CDKN1A MDM2 MITF TP53
25
Show member pathways
12.28 CASP3 CDKN1A MDM2 TP53
26
Show member pathways
12.24 BRAF CASP3 CDKN1A MDM2 NRAS TP53
27 12.19 BRAF CASP3 MDM2 TP53
28 12.19 CASP3 CDKN1A MDM2 NRAS TP53
29
Show member pathways
12.18 BRAF CASP3 NRAS TP53
30 12.17 BRAF CASP3 CDKN1A MMP2 PTGS2 TP53
31 12.17 CASP3 CDKN1A CDKN2A CDKN2B MDM2 NRAS
32 12.16 BRAF CASP3 CDKN1A FGF2 MDM2 MMP2
33
Show member pathways
12.14 BRAF CDKN1A CDKN2B MDM2 NRAS
34 12.14 CDKN1A CDKN2A CDKN2B MDM2 NRAS TP53
35 12.13 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
36 12.11 CDKN1A CDKN2A MDM2 MMP2 TP53
37 12.1 CDKN1A MDM2 MMP2 TP53
38 12.03 BRAF CASP3 NRAS PTGS2
39 12.03 CDKN1A CDKN2A MDM2 NRAS TP53
40 12.01 CDKN1A FGF2 MMP2 PTGS2 TP53
41 11.97 BRAF CDKN1A CDKN2A MDM2 TP53
42 11.92 CASP3 MMP2 NRAS
43 11.89 CASP3 CDKN1A CDKN2B PTGS2 TP53
44 11.89 BRAF CDKN1A CDKN2A MDM2 NRAS TP53
45 11.87 FGF2 MMP2 PTGS2
46 11.86 CDKN1A MDM2 TP53
47
Show member pathways
11.85 CDKN1A MDM2 TP53
48
Show member pathways
11.83 BRAF CASP3 NRAS
49 11.82 CDKN1A MDM2 TP53
50 11.8 CDKN1A NRAS PTGS2

GO Terms for Skin Melanoma

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 BRAF CDKN2A MDM2 MITF TP53
2 angiogenesis GO:0001525 9.89 FGF2 MCAM MMP2 PTGS2
3 response to drug GO:0042493 9.88 CASP3 CDKN1A MDM2 NME1 PTGS2
4 negative regulation of cell proliferation GO:0008285 9.85 CDKN1A CDKN2A CDKN2B NME1 PTGS2 TP53
5 cell cycle arrest GO:0007050 9.8 CDKN1A CDKN2A CDKN2B TP53
6 negative regulation of apoptotic process GO:0043066 9.8 BRAF CASP3 CDKN1A MDM2 MITF PTGS2
7 response to organic substance GO:0010033 9.79 CASP3 CDKN1A PTGS2
8 response to glucocorticoid GO:0051384 9.75 CASP3 CDKN1A PTGS2
9 cellular response to drug GO:0035690 9.74 BRAF NME1 TP53
10 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.72 CDKN1A MDM2 TP53
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 FGF2 MDM2 MMP2
12 response to cAMP GO:0051591 9.7 BRAF NME1 TYR
13 melanin biosynthetic process GO:0042438 9.61 PMEL TYR
14 response to antibiotic GO:0046677 9.61 CASP3 MDM2 TP53
15 negative regulation of fibroblast migration GO:0010764 9.6 BRAF FGF2
16 amyloid fibril formation GO:1990000 9.58 CDKN2A MDM2
17 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 CASP3 CDKN1A CDKN2A
18 signal transduction by p53 class mediator GO:0072331 9.51 CDKN1A TP53
19 negative regulation of phosphorylation GO:0042326 9.5 CDKN1A CDKN2A CDKN2B
20 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
21 cytokine-mediated signaling pathway GO:0019221 9.43 CASP3 CDKN1A FGF2 MMP2 PTGS2 TP53
22 replicative senescence GO:0090399 9.33 CDKN1A CDKN2A TP53
23 Ras protein signal transduction GO:0007265 9.02 CDKN1A CDKN2A FGF2 NRAS TP53

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.13 CDKN2A MDM2 TP53
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CASP3 CDKN1A CDKN2A CDKN2B

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....